JMP Securities Starts Turning Point Therapeutics Inc. (TPTX) at Market Outperform
JMP Securities analyst Silvan Tuerkcan initiates coverage on Turning Point Therapeutics Inc. (NASDAQ: TPTX) with a Market Outperform rating.
Shares of Turning Point Therapeutics Inc. closed at $103.46 yesterday.
You May Also Be Interested In
- UPDATE: Oppenheimer Starts Golub Capital BDC (GBDC) at Outperform
- UBS Starts Sensata Technologies (ST) at Neutral
- UPDATE: JMP Securities Starts Inhibrx Inc. (INBX) at Market Outperform
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!